What is Deciphera?
Deciphera is a specialized biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines for cancer patients. The company distinguishes itself through its proprietary switch-control kinase inhibitor platform, which allows for precise targeting of disease-driving kinases. Its flagship product, QINLOCK, has achieved significant regulatory milestones, including FDA approval for the treatment of fourth-line gastrointestinal stromal tumor (GIST). With a robust portfolio of clinical-stage candidates, Deciphera is effectively bridging the gap between advanced molecular research and global patient care, maintaining a strong presence in key international markets including Australia, Canada, and China.
How much funding has Deciphera raised?
Deciphera has raised a total of $994.5M across 6 funding rounds:
Series B
$90M
Series C
$52M
Stock Offering
$127.5M
Stock Offering
$400M
Stock Offering
$175M
Stock Offering
$150M
Series B (2015): $90M with participation from SV Life Sciences and New Leaf Venture Partners
Series C (2017): $52M led by Viking Global Investors, Redmile Group, Sphera Global Healthcare Fund, and New Leaf Venture Partners
Stock Issuance/Offering (2017): $127.5M, investors not publicly disclosed
Stock Issuance/Offering (2019): $400M, investors not publicly disclosed
Stock Issuance/Offering (2020): $175M, investors not publicly disclosed
Stock Issuance/Offering (2022): $150M, investors not publicly disclosed
Key Investors in Deciphera
Viking Global Investors
Viking Global Investors is a global investment firm specializing in research-intensive, long-term focused investments using fundamental analysis to select public and private equity interests across industries and geographies.
New Leaf Venture Partners
New Venture Partners LLC is a global venture capital firm dedicated to corporate technology spinouts, providing a bridge between technology corporations and traditional venture capital through a systematic approach to commercializing innovations.
SV Life Sciences
SV Health Investors is a specialist investment firm backing innovative health care and life science companies, partnering with management to provide capital and sector expertise from early growth through scale.
What's next for Deciphera?
Looking ahead, Deciphera is positioned to leverage its recent capital influx to scale its research and development operations and expand the clinical utility of its kinase inhibitor platform. The company's strategic roadmap focuses on advancing its pipeline of product candidates while maximizing the commercial reach of its existing approved therapies. As the firm transitions into a more mature phase of enterprise-level growth, the focus will likely shift toward optimizing operational efficiencies and exploring new therapeutic indications. This sustained financial backing provides the necessary runway to navigate the rigorous regulatory landscape and maintain a competitive edge in the rapidly evolving oncology market.
See full Deciphera company page
